Adagene (ADAG) Cash & Equivalents (2019 - 2025)

Adagene (ADAG) has 7 years of Cash & Equivalents data on file, last reported at $74.5 million in Q4 2025.

• On a quarterly basis, Cash & Equivalents fell 12.53% year-over-year to $74.5 million in Q4 2025; TTM through Dec 2025 was $74.5 million, a 12.53% decrease from a year earlier, with the FY2025 full-year figure at $74.5 million, down 12.53% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $74.5 million, up from $62.8 million in the prior quarter.
• Over the last five years, Cash & Equivalents for ADAG reached as high as $208.3 million in Q2 2021 and fell as low as $128.76 in Q2 2023.
• Historically, Cash & Equivalents has averaged $95.5 million across 5 years, with a median of $90.4 million in 2024.
• Across the five-year window, Cash & Equivalents plunged 100.0% in 2022 and soared 74303888.22% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $174.4 million in 2021, then fell by 17.57% to $143.8 million in 2022, then slipped by 23.53% to $109.9 million in 2023, then declined by 22.5% to $85.2 million in 2024, then dropped by 12.53% to $74.5 million in 2025.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $74.5 million in Q4 2025, $62.8 million in Q2 2025, and $85.2 million in Q4 2024.